ELUTIA Business Summary

Elutia Inc. (ELUT) is a commercial-stage regenerative medicine company that generates revenue through the sale of drug-eluting biomatrix products designed to enhance compatibility between medical devices and patients. The company’s business is organized into three primary segments: Women’s Health, Cardiovascular, and Device Protection. Following the strategic $88 million divestiture of its BioEnvelope cardiac assets to Boston Scientific in late 2025, Elutia has pivoted its core focus toward its proprietary drug-eluting biomatrix platform for plastic and reconstructive surgery, specifically the NXT-41x program for breast reconstruction. Its current portfolio features SimpliDerm, a human acellular dermal matrix for tissue repair, and the upcoming NXT-41x base matrix, which targets the reduction of post-operative infections. Elutia competes with diversified medical technology giants such as Medtronic, Smith & Nephew, and NuVasive, distinguishing itself as a specialized pioneer in antibiotic-eluting biologics that mitigate complications like capsular contraction and device erosion. Elutia was co-founded by President and CEO C. Randal Mills, Ph.D., and Chief Scientific Officer Michelle LeRoux Williams, Ph.D., both of whom previously led Osiris Therapeutics, where they commercialized five cell-therapy products and generated over $1 billion in shareholder value. The leadership team includes CFO Matthew Ferguson and VP of Product Development Dana Yoo, Ph.D., an expert in human tissue-based therapeutics who spearheaded the development of the EluPro platform. The company’s board is led by Executive Chairman Kevin Rakin, co-founder of HighCape Capital—Elutia’s controlling stockholder—and features MedTech veteran Guido J. Neels, former COO of Guidant Corporation. Notable institutional backing from firms such as Nantahala Capital Management and Silverarc Capital Management underscores investor confidence in the company’s transition toward high-margin, drug-eluting regenerative solutions.